Status:
COMPLETED
A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy
Lead Sponsor:
Children's Hospital of The King's Daughters
Collaborating Sponsors:
Novartis
Genentech, Inc.
Conditions:
ALLERGIC ASTHMA
Eligibility:
All Genders
8-18 years
Phase:
PHASE4
Brief Summary
The researcher proposes to assess levels of sputum inflammatory markers (eosinophils, eosinophil cationic protein (ECP), neutrophils IL-8) before and while on anti-IgE therapy in a pediatric populatio...
Detailed Description
Objectives: Primary: Describe inflammatory cell types in study patients and compare changes in inflammatory cell patterns before and during anti-IgE therapy. Secondary:Describe patterns of sputum eo...
Eligibility Criteria
Inclusion
- Moderate to severe allergic asthma, uncontrolled on conventional therapy
Exclusion
- History of systemic illness, currently on other immune modulators like immunotherapy, IVIg
- Pregnancy
- IgE level \>1300
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00283504
Start Date
January 1 2006
End Date
January 1 2009
Last Update
February 19 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.